take over, page-5

There are no take over rumours I've hear of.

Longer term, bigpharma could be interested in the antibody and AIM programs. Successful completion of Phase II trials could seen to be a likely time for any offers but who would know. Such trials won't IMHO be completed before the end of 2014..

Successful completion of Phase III trials the antibody and AIM programs could eventially be worth around half a billion each. A previous newsletter actually suggested this was the sort of money such programs go for. With a partner, cdy's share may be significantly less than this but the residual numbers would still be very large given the market scope for each of these programs.

cheers